News and Views
Nature Genetics 41, 509 - 510 (2009)
doi:10.1038/ng0509-509
TMPRSS2-ERG and PTEN loss in prostate cancer
Jeremy A Squire1
-
Jeremy A. Squire is in the Department of Pathology and Molecular Medicine and the NCIC Clinical Trials Group at Queen's University, Kingston, Ontario, Canada.
e-mail: squirej@queensu.ca
Abstract
Two studies show that the common recurrent gene fusion between TMPRSS2 and ERG promotes prostate cancer in both mouse and humans when PTEN is concurrently lost. In human prostate cancer, the presence of both these aberrations may be indicative of poor prognosis, suggesting that preclinical therapeutic research should target both of these pathways.
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
NEWS AND VIEWS
Prostate cancer PSA as an intermediate end point in clinical trialsNature Reviews Urology News and Views (01 Sep 2009)
RESEARCH
Intestinal tumor progression is promoted by decreased apoptosis and dysregulated Wnt signaling in Ceacam1 −/− miceOncogene Original Article
Effects of the Nitrone Radical Scavengers PBN and S-PBN on In Vivo Trapping of Reactive Oxygen Species After Traumatic Brain Injury in RatsJournal of Cerebral Blood Flow & Metabolism Original Article
Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostateNature Genetics Letter (01 May 2009)
See all 11 matches for Research
